


Azacitidine

CAS No. 320-67-2

Reasonably anticipated to be a human carcinogen
First Listed in the *Eighth Report on Carcinogens* (1998)



Carcinogenicity

Azacitidine (5-Azacytidine; 5-AzaC) is *reasonably anticipated to be a human carcinogen* based on evidence of malignant tumor formation at multiple tissue sites in multiple species of experimental animals (NCI 1978, Luz and Murray 1988, IARC 1990).

5-AzaC, when administered by intraperitoneal (i.p.) injection, induced lymphoreticular neoplasms and skin and lung tumors in male and/or female mice (NCI 1978, Luz and Murray 1988, IARC 1990), and leukemia, lymphoma, and tumors of the liver and lung in offspring of treated pregnant dams (IARC 1990). In male rats, 5-AzaC administered i.p. induced squamous cell carcinoma of the skin and interstitial-cell tumors of the testes, and appeared to increase the incidence of non-testis tumors in male offspring of treated dams (IARC 1990).

No data were available to evaluate the carcinogenicity of 5-AzaC in humans (IARC 1990).

Additional Information Relevant to Carcinogenicity

Using an initiation-promotion experimental design, chronic i.p. treatment of male rats, previously acutely administered *N*-nitrosodiethylamine (DEN) and partially hepatectomized, with 5-AzaC resulted in a synergistic increase in the frequency of liver, lung, and skin tumors (Carr *et al.* 1988, IARC 1990).

The carcinogenic/enhancement activity of 5-AzaC has been postulated to result directly or indirectly from its ability to inhibit DNA methylation (Harrison *et al.* 1983, Kerbel *et al.* 1984, Kerbel *et al.* 1986, Takenaga 1986, Glover *et al.* 1987, Glover and Leyland-Jones 1987, Jones and Buckley 1990, Haaf 1995). Altered levels of DNA methylation can affect gene expression (Cedar 1988, IARC 1990, Fajkus *et al.* 1992, Velge *et al.* 1995), with hypomethylation being associated with the expression of genes that are normally silent or downregulated (Jones *et al.* 1983, Nyce *et al.* 1983, Riggs and Jones 1983, Collard *et al.* 1989, Jones and Buckley 1990, Pascale *et al.* 1993). In addition, 5-AzaC in the absence of metabolic activation is positive in a wide variety of prokaryotic, lower eukaryotic, and mammalian *in vitro* test systems, inducing DNA damage and mutations (base-pair substitution mutations only) in prokaryote systems; mitotic recombination, gene conversion, and gene mutations in somatic and germ cells of lower eukaryotes (yeast, *Drosophila*, plants); and DNA damage, chromosomal aberrations, mutations (but not point), and morphological transformation in cultured mammalian cells. Studies to evaluate the genetic activity of 5-AzaC in somatic cells of mammals have not been reported; however, it was reported as negative for dominant lethal mutations in mice (IARC 1990).

No data were available to suggest that the mechanisms thought to account for tumor induction by 5-AzaC in experimental animals would not also operate in humans.

Properties

5-AzaC is a white crystalline powder with a melting point of 235°C to 237°C. It is soluble in water, ethanol, acetone, chloroform, hexane, and dimethyl sulfoxide. 5-AzaC is very unstable in aqueous media, with rapid degradation to complex products occurring within hours of dissolution in intravenous solutions at room temperature (IARC 1990).

Use

5-AzaC is an antineoplastic agent that has been used as an investigational drug for the treatment of patients with acute myeloblastic anemia, acute lymphoblastic leukemia, and myelodysplastic syndromes (IARC 1990, Pharmion 2001, Santini *et al.* 2001). 5-AzaC has been used clinically in cancer treatment trial protocols in combination with other antineoplastic agents such as vincristine, prednisone, vinblastine, cytarabine, or amsacrine (IARC 1990). 5-AzaC (alone or in combination with phenylbutyrate or amifostine) is currently being tested in at least seven clinical trials for the following conditions: beta thalassemia, acute myeloid leukemia, myelodysplastic syndrome, advanced or metastatic solid tumors, non-Hodgkins lymphoma, multiple myeloma, non-small cell lung cancer, and prostate cancer (ClinicalTrials.gov 2001).

Production

5-AzaC is synthesized in Germany. It can be prepared by synthetic methods or can be isolated from a culture of the bacterium *Streptovorticillium ladakanus* (IARC 1990). No data on imports or exports of 5-AzaC were available. Chem Sources (2001) listed 11 U.S. suppliers of 5-AzaC.

Exposure

The primary routes of potential human exposure to 5-AzaC are intravenous and intramuscular injection and intravenous infusion at daily doses of 40 to 750 mg/m² (IARC 1990). Occupational exposure may occur for workers formulating or packaging the solutions and for health care professionals administering the drug. The National Occupational Exposure Survey (1981-1983) indicated that 1,069 workers, including 699 women, potentially were exposed to 5-AzaC (NIOSH 1990). This estimate was derived from total observations of the use of the actual compound (48%) and trade name products (52%).

Regulations and Guidelines

No specific regulations or guidelines relevant to reduction of exposure to 5-AzaC were identified.

REFERENCES

- Carr, B. I., S. Rahbar, Y. Asmeron, A. Riggs and C. D. Winberg. 1988. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. *Br J Cancer* 57(4): 395-402.
- Cedar, H. 1988. DNA methylation and gene activity. *Cell* 53(1): 3-4.
- ChemSources. 2001. Chemical Sources International, Inc. <http://www.chemsources.com>.
- ClinicalTrials.gov. 2001. Azacitidine. National Institute of Health. <http://clinicaltrials.gov> and search "azacitidine".
- Collard, J. G., G. G. Habets, R. van der Kammen and E. Scholtes. 1989. Genetic basis of T-lymphoma invasion. *Invasion Metastasis* 9(6): 379-90.
- Fajkus, J., B. Vyskot and M. Bezdek. 1992. Changes in chromatin structure due to hypomethylation induced with 5-azacytidine or DL-ethionine. *FEBS Lett* 314(1): 13-6.
- Glover, A. B. and B. Leyland-Jones. 1987. Biochemistry of azacitidine: a review. *Cancer Treat Rep* 71(10): 959-64.
- Glover, A. B., B. R. Leyland-Jones, H. G. Chun, B. Davies and D. F. Hoth. 1987. Azacitidine: 10 years later. *Cancer Treat Rep* 71(7-8): 737-46.
- Haaf, T. 1995. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. *Pharmacol Ther* 65(1): 19-46.
- Harrison, J. J., A. Anisowicz, I. K. Gadi, M. Raffeld and R. Sager. 1983. Azacytidine-induced tumorigenesis of CHEF/18 cells: correlated DNA methylation and chromosome changes. *Proc Natl Acad Sci U S A* 80(21): 6606-10.
- IARC. 1990. *Pharmaceutical Drugs. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans*, vol. 50. Lyon, France: International Agency for Research on Cancer. 415 pp.
- Jones, P. A. and J. D. Buckley. 1990. The role of DNA methylation in cancer. *Adv Cancer Res* 54: 1-23.
- Jones, P. A., S. M. Taylor and V. Wilson. 1983. DNA modification, differentiation, and transformation. *J Exp Zool* 228(2): 287-95.
- Kerbel, R. S., P. Frost, R. Liteplo, D. A. Carlow and B. E. Elliott. 1984. Possible epigenetic mechanisms of tumor progression: induction of high-frequency heritable but phenotypically unstable changes in the

SUBSTANCE PROFILES

- tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment. *J Cell Physiol Suppl* 3: 87-97.
- Kerbel, R. S., R. Liteplo and P. Frost. 1986. On the possible contribution of DNA hypomethylation to the induction of high frequency and heritable drug-induced alterations in the malignant phenotype. *Prog Clin Biol Res* 212: 293-304.
- Luz, A. and A. B. Murray. 1988. Sudden outbreak of a leukemia-like lesion in female CBA mice after repeated injections of 5-azacytidine. *J Cancer Res Clin Oncol* 114(5): 525-7.
- NCI. 1978. Bioassay of 5-Azacytidine (CAS No. 320-67-2) for Possible Carcinogenicity. Technical Report Series No 42. DHEW (NIH) Publication No. 78-842. Bethesda, MD: National Institute of Health.
- NIOSH. 1990. National Occupational Exposure Survey (1981-83). Unpublished provisional data as of 7/1/90. Cincinnati, OH: U. S. Department of Health and Human Services.
- Nyce, J., S. Weinhouse and P. N. Magee. 1983. 5-Methylcytosine depletion during tumour development: an extension of the miscoding concept. *Br J Cancer* 48(4): 463-75.
- Pascale, R. M., M. M. Simile and F. Feo. 1993. Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy. *Anticancer Res* 13(5A): 1341-56.
- Pharmion. 2001. <http://www.pharmion.com> (select therapeutics, then hematology and oncology products).
- Riggs, A. D. and P. A. Jones. 1983. 5-methylcytosine, gene regulation, and cancer. *Adv Cancer Res* 40: 1-30.
- Santini, V., H. M. Kantarjian and J. P. Issa. 2001. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. *Ann Intern Med* 134(7): 573-86.
- Takenaga, K. 1986. Modification of the metastatic potential of tumor cells by drugs. *Cancer Metastasis Rev* 5(2): 67-75.
- Velge, P., B. Kaeffer, E. Botreau and N. Van Langendonck. 1995. The loss of contact inhibition and anchorage-dependent growth are key steps in the acquisition of *Listeria monocytogenes* susceptibility phenotype by non-phagocytic cells. *Biol Cell* 85(1): 55-66.
-